Ads
related to: myotonic muscular dystrophy
Search results
Firefighters fill their boots for the Muscular Dystrophy Association
KNBN Rapid City· 1 day agoRapid City firefighters at Rapid City intersections asking for donations for MDA. The funds for ...
Why This Biotech Just Launched — Again — After Its 166% Run
Investor's Business Daily· 3 days agoDyne studied drugs it calls DYNE-101 and DYNE-251 in patients with myotonic dystrophy type 1 and...
Dyne Therapeutics Discloses Positive Trial Data for DYNE-101, DYNE-251 Treatments
Market Watch· 4 days agoBy Denny Jacob Dyne Therapeutics disclosed positive clinical data from trials on treatments for patients with myotonic dystrophy type 1 and Duchenne muscular...
Small Business - The Roanoke-Chowan News-Herald | The Roanoke-Chowan News-Herald
Roanoke-Chowan News-Herald· 5 days agoWALTHAM, Mass., May 19, 2024 (GLOBE NEWSWIRE) -- Dyne Therapeutics, Inc. (Nasdaq: DYN), a clinical-stage muscle disease company focused on advancing innovative life-transforming therapeutics for people living with genetically driven diseases
The Petri Dish: Dyne’s public offering, Kronos’ new CFO - Boston Business Journal
The Business Journals· 14 hours agoAt the start of this week, Waltham’s Dyne Therapeutics Inc. had positive news to share on two...
JPMorgan maintains overweight rating on Dynatrace with $60 target By Investing.com
Investing.com· 4 days agoOn Monday, JPMorgan (NYSE:JPM) reiterated its Overweight rating with a $60.00 price target for...
Dyne shares jump on trial data for muscle disease drugs
BioPharma Dive via Yahoo Finance· 4 days agoUpdated study results for the biotech’s medicines for myotonic dystrophy Type 1 and Duchenne ...
ALS Awareness Month: What is the disease, the research being done and one dad's inspiring story
ABC7 New York· 7 hours agoIn this special edition of Eyewitness News Extra Time, we're focusing on ALS: what it is, the...
Avidity Biosciences Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
FOX 59 Indianapolis· 2 days agoAvidity Biosciences, Inc. (Nasdaq: RNA), a biopharmaceutical company committed to delivering a new class of RNA therapeutics called Antibody Oligonucleotide Conjugates (AOCs™), today announced ...
Up 165% This Year, Will Dyne Therapeutics Continue Its Stellar Run?
Forbes· 2 days agoThis move came in after the company released a positive clinical trial data for its experimental...
